• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022 - Product Image

EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022

  • Published: December 2012
  • 76 pages
  • GlobalData

EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022

Summary

Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system, destroying or impairing their function. The most advanced stage of HIV infection is acquired immunodeficiency syndrome (AIDS). Approximately 34 million people are living with HIV around the world, with an estimated 2.7 million new infections each year, and the size of HIV/AIDS incident and prevalent populations vary widely between countries (UNAIDS, 2011). GlobalData epidemiologists forecast incident cases of HIV will increase 9.7% over the next decade in the 10 markets, from 276,590 incident cases in 2012 to 303,365 incident cases in 2022. In the 10 markets, GlobalData epidemiologists calculated that approximately 5.39 million prevalent cases of HIV occurred in 2012. The number of prevalent cases of HIV is expected to grow almost 15% over the next decade to 6.1 million by 2022. Although all countries covered in this report have introduced a number of preventive programs and government-led interventions among HIV high-risk populations, the burden of HIV is expected to continue. Sustained levels READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
3 Epidemiology
3.1 Risk Factors and Comorbidities
3.1.1 Condoms decrease HIV transmission by nearly 90%
3.1.2 Bodily fluids are the second most common mode of HIV transmission
3.1.3 Antiretrovirals reduce perinatal transmission as much as 99%
3.1.4 HIV/HCV co-infection complicates treatment options and accelerates liver damage
3.1.5 13% of new TB cases are among people with HIV
3.2 Global Trends
3.2.1 The US
3.2.2 France
3.2.3 Germany
3.2.4 Italy
3.2.5 Spain
3.2.6 The UK
3.2.7 Japan
3.2.8 Brazil
3.2.9 India
3.2.10 China
3.3 Forecast Methodology
3.3.1 Sources used
3.4 Forecast Assumptions and Methods
3.4.1 Incident Cases
3.4.2 Prevalent Cases
3.5 Sources Not Used
3.6 Epidemiology Forecast
3.6.1 Incidence
3.6.2 Prevalence
3.6.3 Prevalent Cases of HIV Segmented by Comorbidities
3.6.4 Antiretroviral Use in Prevalent HIV Cases
3.7 Discussion
3.8 Limitations of This Analysis
3.9 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About Us
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

1.1 List of Tables
Table 1: HIV Prevention Strategies
Table 2: Sources of HIV Incidence Data
Table 3: Sources of HIV Prevalence Data
Table 4: 10 Major Markets, HIV Incident Cases, Ages 15–69 Years, Men and Women, N, Select Years, 2012–2022
Table 5: 10 Major Markets, HIV Incident Cases, By Age, Men and Women, N (Row %), 2012
Table 6: 10 Major Markets, HIV Prevalent Cases, Ages 15–69 Years, Men and Women, N, Select Years, 2012–2022
Table 7: 10 Major Markets, HIV Prevalent Cases, By Age, Men and Women, N (Row%), 2012
Table 8: 10 Major Markets, Comorbidity and Pregnancy in Prevalent Cases of HIV, Ages 15–69 Years, Both Sexes, N (%), 2012
Table 9: 10 Major Markets, Antiretroviral Use in Prevalent HIV Cases, Ages 15–69 Years, Men and Women, N (%), 2012

1.2 List of Figures
Figure 1: Global Trends in HIV, N, Selected Years, 2001–2010
Figure 2: The US, HIV Incidence, By Race/Ethnicity, N, 2009
Figure 3: France, HIV Incidence, By Sex, Rate per 100,000 Population, 2003–2010
Figure 4: France, HIV Incident Cases and AIDS-related Mortality, By Sex, N, 2003–2010
Figure 5: Germany, HIV Incidence, By Sex, Rate per 100,000 Population, 2001–2010
Figure 6: Germany, HIV Incident Cases and AIDS-related Mortality, By Sex, N, 2001–2010
Figure 7: Italy, HIV Incidence, By Sex, Rate per 100,000 population, 2004–2010
Figure 8: Italy, HIV Incident Cases and AIDS-related Mortality, By Sex, N, 2004–2010
Figure 9: Spain, HIV Incidence, By Sex, Rate per 100,000 Population, 2003–2010
Figure 10: Spain, HIV Incident Cases and AIDS-related Mortality, By Sex, N, 2003–2010
Figure 11: The UK, HIV/AIDS Incident Cases and Mortality, N, 2000–2009
Figure 12: China, Incident and Prevalent Cases of HIV/AIDS and Mortality, N, 2007–2011
Figure 13: 5EU Markets and Japan, HIV Incident Cases, Ages 15–69 Years, Men and Women, N, 2012–2022
Figure 14: The US, Brazil, India, and China, HIV Incident Cases, Ages 15–69 Years, Men and Women, N, 2012–2022
Figure 15: 10 Major Markets, HIV Incidence Cases, By Age, Men and Women, 2012
Figure 16: 10 Major Markets, HIV Incident Cases, Ages 15–69 Years, By Sex, N, 2012
Figure 17: 10 Major Markets, Age-Standardized HIV Incidence Rates, Ages 15–69 Years, Men and Women, Cases per 100,000 Population (Age Adjusted to World Standard Population), 2012
Figure 18: 5EU Markets and Japan, HIV Prevalent Cases, Ages 15–69 Years, Men and Women, N, 2012–2022
Figure 19: The US, Brazil, India and China, HIV Prevalent Cases, Ages 15–69 Years, Men and Women, N, 2012–2022
Figure 20: 10 Major Markets, HIV Prevalent Cases, By Age, Men and Women, N, 2012
Figure 21: 10 Major Markets, HIV Prevalent Cases, Ages 15–69 Years, By Sex, N, 2012
Figure 22: 10 Major Markets, HIV Age-standardized Prevalence, Ages 15–69 Years, Men and Women % (Age Adjusted to World Standard Population), 2012
Figure 23: 10 Major Markets, Comorbidity and Pregnant Women with HIV, Ages 15–69 Years, Both Sexes, N, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos